Sydnexis
PrivateLast Round
VC Round
Apr 15, 2025
Total Funding Raised
$50.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sydnexis is a biopharmaceutical company that develops topical ophthalmic formulations, including its lead candidate SYD-101, aimed at slowing the progression of pediatric myopia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sydnexis Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Sydnexis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Apr 15, 2025 | ||||
| Series B | Aug 10, 2021 | ||||
| Series A | Oct 19, 2017 |
Sydnexis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series A, Series B |
| RA Capital Management | Series A, Series B |
| SC Master Fund | Series B |
| Visionary Ventures | Series B |
| Medicxi | Series A, Series B |
| Bluestem Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 23, 2026
Presented Phase 3 STAR Trial data at the 2026 AAPOS Annual Meeting.
- Mar 23, 2026
New Phase 3 data for SYD-101 presented at AAPOS Annual Meeting.
Sydnexis Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Sydnexis's valuation, stock price, and market status.